← Leaderboards
Brian Patrick Conlon
Univ Of North Carolina Chapel Hill
$5,321,207
Attributed
$7,475,899
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,475,899 · 7
By mechanism
R01$5,679,934 · 3
R21$852,027 · 2
R56$674,578 · 1
K22$269,360 · 1
Top collaborators
- Lance R. Thurlow3 shared
- Thomas Everett Kehl-Fie2 shared
- Vance G Fowler1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Bruce A Cairns$5,721,017
- Amanda Zoyla Velez$127,687
- Anthony R. Richardson$8,031,146
- Lauren Christine Radlinski$387,944
- Matthew Louis Hirsch$4,267,556
Others in their field
Other Emerging Leaders on “Antibiotic Therapy”
- Terry Roemer · Prokaryotics, Inc.$11,277,103
- Thomas Dick · Rbhs-New Jersey Medical School$9,074,893
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$7,830,490
- Jeongmin Song · Cornell University$7,814,606
- Denis Marc Daigle · Venatorx Pharmaceuticals, Inc.$7,512,530
- Angela Ramona Branche · University Of Rochester$6,479,753
Research focus
Antibiotic TherapyStaphylococcus AureusAntibioticsInfectionIn VivoAntibiotic ToleranceTreatment FailureGrowthAntibiotic ResistanceEnvironmentPredispositionMediatingBactericideProductionAntibiotic SusceptibilityBacterial InfectionsPathogenPhysiologicalFailureBacteriaMutantNutrientExperimental StudyMicrobial Biofilms
Grant awards (17)
Calprotectin and Antibiotic Activities at the Infection Interface$770,037
R01 · FY2025 · AI · contact PI
Diabetes and Antibiotic Treatment Failure$684,320
R01 · FY2025 · AI · contact PI
Determining how neutrophil activities contribute to antibiotic treatment failure$421,067
R21 · FY2025 · AI · contact PI
Calprotectin and Antibiotic Activities at the Infection Interface$784,059
R01 · FY2024 · AI · contact PI
Diabetes and Antibiotic Treatment Failure$684,320
R01 · FY2024 · AI · contact PI
Diabetes and Antibiotic Treatment Failure$712,070
R01 · FY2023 · AI · contact PI
The contribution of respiratory burst to antibiotic failure in Staphylococcus aureus bacteremia$674,578
R56 · FY2022 · AI · contact PI
Antibiotic activities against S. aureus during P. aeruginosa co-infection$384,736
R01 · FY2022 · AI · contact PI
Identifying the contribution of zinc limitation to antibiotic tolerance during S. aureus infection$190,073
R21 · FY2022 · AI · contact PI
Antibiotic activities against S. aureus during P. aeruginosa co-infection$384,736
R01 · FY2021 · AI · contact PI
Identifying the contribution of zinc limitation to antibiotic tolerance during S. aureus infection$240,887
R21 · FY2021 · AI · contact PI
Antibiotic activities against S. aureus during P. aeruginosa co-infection$459,754
R01 · FY2020 · AI · contact PI
Antibiotic activities against S. aureus during P. aeruginosa co-infection$384,736
R01 · FY2019 · AI · contact PI
Antibiotic activities against S. aureus during P. aeruginosa co-infection$46,430
R01 · FY2019 · AI · contact PI
Antibiotic activities against S. aureus during P. aeruginosa co-infection$384,736
R01 · FY2018 · AI · contact PI
Investigating S. aureus persister formation under physiological conditions$107,680
K22 · FY2018 · AI · contact PI
Investigating S. aureus persister formation under physiological conditions$161,680
K22 · FY2017 · AI · contact PI